Bhavani P K

Dr. Bhavani P K

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
BKBhavani P K
Bhavani P K
NPNatarajan Alangudi Palaniappan
Natarajan Alangudi Palaniappan
TMTamizhselvan Manoharan
Tamizhselvan Manoharan
PPPaul Kumaran Paramasivam
Paul Kumaran Paramasivam
JSJitendra Kumar Saini
Jitendra Kumar Saini
SSSoumya Swaminathan
Soumya Swaminathan
Globally, no trial data are available on head-to-head comparison between 10 mg/kg and 25/35 mg/kg rifampicin in treating pulmonary tuberculosis during study initiation. A multicentric, phase IIb randomized trial recruited 333 new culture-positive, drug-sensitive adult patients with pulmonary tuberculosis to compare safety and efficacy of high-dose rifampicin (R25/R35), against conventional dose (R10) given daily for 8 weeks followed by standard doses for 16 weeks. Main outcomes were treatment-emergent grade 3/4 adverse events (AEs) and time-to-culture conversion in liquid media, assessed by division of AIDS system for grading the severity of adverse events division of AIDS criteria and Kaplan-Meier methods. In a modified intention-to-treat population of 323 patients (R10: 105/R25: 112/R35: 106), grade 3/4 AEs were reported in 34 patients (R10: 9.5% [10/105], R25: 9.8% [11/112], R35: 12.3% [13/106]) during the intensive phase. Among 23 patients (R10: 3.8% [4/105], R25: 6.3% [7/112], R35: 11.3% [12/106]) with grade 3/4 hepatotoxicity, 15 (R10: 1.9% [2/105], R25: 3.6% [4/112], R35: 8.5% [9/106]) had grade 3/4 hyperbilirubinemia and 9 patients (R10: 1.0% [1/105], R25: 0.9% [1/112], R35: 6.6% [7/106]) developed clinical jaundice. Significant differences observed only between R10 and R35 with hepatotoxicity (P = .039), hyperbilirubinemia (P = .031), clinical jaundice (P = .032), and treatment interruption (P = .039). Eighteen serious AEs and 6 deaths (R10: 3/R25: 1/R35: 2) occurred during study period. Time to stable culture conversion in liquid media was faster in R25 (adjusted hazard ratio, 1.71; 95% confidence interval [CI], 1.26–2.31 [solid: 1.97; 95% CI, 1.46–2.67]) and R35 (1.81; 95% CI, 1.33–2.48 [solid: 2.24; 95% CI, 1.64–3.06]), than R10 (34 vs 44 days). R25 had no failure/relapse. Hepatotoxicity, clinical jaundice, and treatment interruptions occurred significantly higher with R35 than R10. Because R25 was comparably safe as R10 and also highly efficacious than R10, it may be considered for implementation. Clinical Trials Registration. CTRI/2017/12/010951. https://tidbitapp.io/tidbits/safety-and-efficacy-of-25-mg-and-35-mg-versus-10-mg-rifampicin-in-pulmonary-tb-a-randomised-trial/

28 November 2023 in Therapeutic Drug Monitoring
Verified
Journal Article
Open access
AKAgibothu Kupparam Hemanth Kumar
Agibothu Kupparam Hemanth Kumar
AKAbhijit Vasantrao Kadam
Abhijit Vasantrao Kadam
RKRamesh Karunaianantham
Ramesh Karunaianantham
TMTamizhselvan Manoharan
Tamizhselvan Manoharan
CPChandrasekaran Padmapriyadarsini
Chandrasekaran Padmapriyadarsini
MTMetrif Team
Metrif Team
Background: To evaluate the effect of metformin on the plasma levels of rifampicin, isoniazid, and pyrazinamide in patients with drug-sensitive pulmonary tuberculosis being treated with first-line antituberculosis treatment (ATT) and to assess the influence of gene polymorphisms on the metabolic pathway of metformin and plasma levels of antitubercular drugs. Methods: Nondiabetic adults aged 18–60 years with pulmonary tuberculosis were randomized to either the standard ATT (ATT group) or ATT plus metformin (METRIF group) groups in a phase IIB clinical trial. An intensive pharmacokinetic study with blood collection at 0 hour (predosing), followed by 1, 2, 4, 6, 8, and 12 hours after dosing was conducted during the first month of treatment in a subset of 60 study participants after a minimum of 14 doses. Plasma concentrations of rifampicin, isoniazid, pyrazinamide, and metformin were measured by high-performance liquid chromatography using validated methods, and pharmacokinetic parameters and OCT1 and MATE1 gene polymorphisms were compared between the groups. Results: Significant increases in the clearance of rifampicin, isoniazid, and pyrazinamide were observed in patients in the METRIF group (n = 29) compared with those in the ATT group (n = 31). The AA genotypes of the single-nucleotide polymorphism of rs2289669 (MATE1) in the METRIF group showed a significantly decreased area under the concentration–time curve to the last observation point and increased clearance of rifampicin. Conclusions: Metformin altered rifampicin and isoniazid plasma concentrations in patients receiving antituberculosis treatment for pulmonary tuberculosis with little effect on sputum conversion at the end of treatment. Studies with larger sample sizes are needed to understand host drug–drug interactions.

18 September 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
APArul Nancy Pandiarajan
Arul Nancy Pandiarajan
NKNathella Pavan Kumar
Nathella Pavan Kumar
ARAnuradha Rajamanickam
Anuradha Rajamanickam
BKBhavani P K
Bhavani P K
JBJeyadeepa Bharathi
Jeyadeepa Bharathi
SBSubash Babu
Subash Babu
Background: Antimicrobial peptides are an important component of host defense against Mycobacterium tuberculosis. However, the ability of BCG to induce AMPs as part of its mechanism of action has not been investigated in detail. Methods: We investigated the impact of Bacillus Calmette–Guerin (BCG) vaccination on circulating plasma levels and TB-antigen stimulated plasma levels of AMPs in a healthy elderly population. We assessed the association of AMPs, including Human Beta Defensin 2 (HBD-2), Human Neutrophil Peptide 1-3 (HNP1-3), Granulysin, and Cathelicidin (LL37), in circulating plasma and TB-antigen stimulated plasma (using IGRA supernatants) at baseline (pre-vaccination) and at Month 1 and Month 6 post vaccination. Results: Post BCG vaccination, both circulating plasma levels and TB-antigen stimulated plasma levels of AMPs significantly increased at Month 1 and Month 6 compared to pre-vaccination levels in the elderly population. However, the association of AMP levels with latent TB (LTB) status did not exhibit statistical significance. Conclusion: Our findings indicate that BCG vaccination is linked to heightened circulating levels of AMPs in the elderly population, which are also TB-antigen-specific. This suggests a potential mechanism underlying the immune effects of BCG in enhancing host defense against TB.

28 September 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
NGNandita G
Nandita G
RRRajesh Kumar Radhakrishnan
Rajesh Kumar Radhakrishnan
FSFathima Sumaira
Fathima Sumaira
JVJai Priya Govindasamy Venugopal
Jai Priya Govindasamy Venugopal
BKBhavani P K
Bhavani P K
NKNathella Pavan Kumar
Nathella Pavan Kumar
Background: Type 2 diabetes mellitus (T2DM) increases susceptibility to tuberculosis (TB) and contributes to immune dysregulation, exaggerated inflammation and poor clinical outcomes. Acute-phase proteins (APPs), lung-associated markers (LMs) and TNF superfamily ligands play a crucial role in inflammatory and immune signaling; however, an integrated approach in understanding the inflammatory profile and their immunological association in TB-T2DM remains underexplored. Methods: Plasma levels of APPs and LMs including CRP, SAA1, Haptoglobin, α2M, IDO, CHI3L1, S100A8, S100A9 and granulysin were evaluated for the study cohort of 176 individuals (TB = 44, TB–T2DM = 44, T2DM-only = 44 and healthy-controls = 44). TNF superfamily ligands, including 4-1BBL, APRIL, BAFF, CD30L, CD40L, EDA-1, Fas-L, GITRL, LIGHT, RANKL, NGF- β, TNF-β, TRAIL and TWEAK, were measured using a multiplex immunoassay for 88 individuals (TB = 22, TB–T2DM = 22, T2DM-only = 22 and healthy-controls = 22). Spearman correlation analysis, protein–protein interaction (PPI) network analysis and pathway enrichment analysis were also performed. Results: TB-T2DM individuals exhibited significantly increased inflammatory burden compared with TB, T2DM and HC groups. Increased levels of CRP, SAA1, S100A8, S100A9, haptoglobin, CH3IL1 and α2M were observed (p < 0.05), indicating amplified systemic and pulmonary inflammation. TNF superfamily ligands including BAFF, APRIL, CD40L, GITRL, LIGHT and TRAIL were significantly altered in TB-T2DM individuals, suggesting dysregulated TNF-mediated immune signaling. Correlation analysis revealed strong associations between HbA1c levels and inflammatory markers including BAFF, TRAIL, GITRL, LIGHT, CD40L, APRIL, S100A8 and SAA1 (p < 0.05). Network and enrichment analyses identified significant involvement of cytokine–cytokine receptor interaction, IL-17 signaling, NF-κB signaling, apoptosis and necroptosis pathways. Conclusions: Overall, TB-T2DM comorbidity is characterized by exaggerated inflammatory responses and altered TNF superfamily ligand signaling associated with poor glycemic control. This interconnected immune dysregulation may provide future insights into biomarkers and pathway-related investigation to establish more clinical and biological relevance.